Bipolar affective disorder is a severe and debilitating psychiatric condition characterized by the alternating mood states of mania and depression. Both the molecular pathophysiology of the disorder and the mechanism of action of the mainstays of its treatment remain largely unknown. Here, 1 H NMR spectroscopy-based metabonomic analysis was performed to identify molecular changes in post-mortem brain tissue (dorsolateral prefrontal cortex) of patients with a history of bipolar disorder. The observed changes were then compared to metabolic alterations identified in rat brain following chronic oral treatment with either lithium or valproate. This is the first study to use 1 H NMR spectroscopy to study post-mortem bipolar human brain tissue, and it is the first to compare changes in disease brain with changes induced in rat brain following mood stabilizer treatment. Several metabolites were found to be concordantly altered in both the animal and human tissues. Glutamate levels were increased in post-mortem bipolar brain, while the glutamate/glutamine ratio was decreased following valproate treatment, and c-aminobutyric acid levels were increased after lithium treatment, suggesting that the balance of excitatory/inhibitory neurotransmission is central to the disorder. Both creatine and myo-inositol were increased in the post-mortem brain but depleted with the medications. Lastly, the level of N-acetyl aspartate, a clinically important metabolic marker of neuronal viability, was found to be unchanged following chronic mood stabilizer treatment. These findings promise to provide new insight into the pathophysiology of bipolar disorder and may be used to direct research into novel therapeutic strategies.
Introduction
Bipolar disorder is a chronic psychiatric condition characterized by alternations between the extreme mood states of mania and depression. It causes severe psychosocial dysfunction and is associated with a dramatically increased risk for accidental death and suicide. The disorder is very common, with a prevalence of about 1%, and is a cause of substantial worldwide disability. 1 Despite overwhelming evidence for a biological etiology and pathophysiology, the underlying cause of the disorder remains largely unknown. Previous data have suggested a number of theories to explain bipolar disorder's etiology, including a developmental process, a neurodegenerative pathology and a change in monoamine neurotransmission. None of these have been accepted universally, however. Specific previous findings are mentioned further in the 'Discussion' section when they relate to the results presented here. A number of medications have been used for several decades to help treat the disorder and/or ameliorate symptoms, but the mechanisms of their action remain to be fully elucidated. The mainstays of treatment consist of the mood stabilizers valproic acid (Depakote) and lithium. Valproic acid is a short, branched-chain fatty acid, whereas lithium is a simple monovalent cation. Despite their distinct chemical structures, both compounds can be used to decrease the incidence and severity of mood episodes. 2 Valproic acid as well as lithium have shown protective effects on neural tissue in vivo and in vitro. [3] [4] [5] [6] Both medications have also been found to regulate biochemical processes involved in cellular protection. 7, 8 Furthermore, in vivo magnetic resonance spectroscopy (MRS) of the brain has provided evidence for a neurotrophic/neuroprotective effect of lithium in patients. For example, lithium treatment has been shown to increase both gray matter density and levels of N-acetyl aspartate (NAA), a marker of neuronal viability, in the brain following chronic treatment. [9] [10] [11] Both medications have also been shown to have a number of other effects, including alterations to intracellular and neurotransmitter signaling in the brain. 12 The mechanisms by which these medications exert their effects, however, have yet to be completely determined. Further work is thus needed to understand which of these actions are essential for their efficacy in treating bipolar disorder. 1 H NMR spectroscopy-based metabonomic analysis can be used to monitor a wide range of metabolites in biological samples, allowing for a sensitive, highthroughput molecular screening. [13] [14] [15] NMR spectroscopy is methodologically similar to in vivo MRS, but enables higher resolution of spectra for more accurate quantitation and greater sensitivity, allowing the detection of less abundant metabolites. Although there are many platforms for metabolic profiling (for example, LC-MS, GC-MS, NMR, electrocapillary phoresis-MS), no one technology gives complete coverage of the metabonome. This technique has been used extensively in studies on schizophrenia, [16] [17] [18] [19] Alzheimer's disease, 20 Huntington's disease, 21 Batten disease 22 and human brain tumors 23 (for detailed reviews on metabonomics, see Holmes et al. 24 and Lenz and Wilson
25
). These studies have identified a number of biochemical alterations that may be occurring as part of the pathogenesis of these diseases. For example, Pears et al. 22 identified glutamate and GABA alterations in aqueous brain extracts of a mouse model of Batten disease.
In this study, a 1 H NMR metabonomics approach was used to identify molecular alterations in the postmortem dorsolateral prefrontal cortex from patients who died with a diagnosis of bipolar affective disorder. Previous post-mortem and imaging studies have demonstrated disturbances in this region in bipolar patients. 26, 27 It is thought to be involved in the control of volition, judgment, affect and emotions; all processes clearly disturbed in the acute episodes of bipolar disorder. The same metabonomics approach was also employed to characterize changes in the metabolite profiles of rat brain tissue after chronic oral treatment with the mood stabilizers lithium and valproate. Data obtained from human and animal tissue were then compared, to identify key metabolites associated with both the pathophysiology and treatment of the disorder. The analysis revealed novel metabolic changes associated with the drug treatments and allowed for the neuronal viability marker, NAA, to be quantitated in a controlled animal paradigm. By comparing drug-treated animal samples to human post-mortem tissue, biological functions central to the pathogenesis and treatment of the disorder have been identified. The data imply that a metabolic disturbance may exist in the brain of bipolar patients and that this disturbance is corrected through treatment with medications.
Materials and methods
Human post-mortem tissue Fresh frozen dorsolateral prefrontal cortex tissue (Brodmann area 9) from both white and gray matter of 10 bipolar disorder and 10 matched control individuals was obtained from the Neuropathology Consortium of the Stanley brain collection (Stanley Medical Research Institute, USA). Demographic data including medication history and condition of patient samples were also obtained from the institute (Table 1) . For a detailed description of patient sample preparation, see Torrey et al. 28 Ethics approval for brain collection is held by the Stanley Medical Research Institute and ethics approval was received from the Cambridge Local Research Ethics Committee for use of human post-mortem tissue.
Animal and drug treatments
All experiments were approved by the National Institutes of Health guidelines on the care and use of animals. Male Wistar Kyoto rats (150-250 g) were housed three to four per cage with access to food and water ad libitum and were maintained under a 12 h light/dark cycle. After a 1-week acclimatization period, animals were fed either regular chow (n = 9), lithium carbonate chow (2.4 g kg À1 ) (n = 9) or valproate chow (20 g kg À1 ) (n = 10) for 28 days. These doses of medications have previously been shown to produce similar serum levels of the medications within the human therapeutic range. 7 In addition to tap water, all animals had a bottle of saline available to minimize electrochemical imbalances from any diuretic properties of the medications. At the end of treatment, rats were euthanized by decapitation between 0900 and 1159 hours and trunk blood was collected to determine drug serum concentration. Brain tissue was removed and cortex, hippocampus and striatum samples were dissected on ice, and frozen at À80 1C. Serum analysis yielded lithium levels 0.76 ± 0.15 mM and valproate levels 60.48±28.5 mg ml
Preparation of tissue extracts from rat brain Frozen tissue samples were weighed before being homogenized in a 1 ml solution of acetonitrile:deionized water (1:1) as described previously. 29, 30 Homogenates were centrifuged at 4800 g for 10 min. Supernatants were removed and left to dry overnight to allow complete evaporation of acetonitrile before being freeze-dried at À70 1C. H NMR spectra were acquired at 700 MHz using a conventional solvent suppressed pulse/acquire sequence based on a standard 1D pulse sequence (noesypr1d) to suppress baseline artifacts resulting from B 0 and B 1 field inhomogenieties (RD Àp/2Àt 1 Àp/2Àt m Àp/2, TR = 3 s). In this sequence, a secondary radiofrequency irradiation is applied at the water resonance frequency during the relaxation delay of 3 s and the mixing period (t m = 150 ms), with t 1 fixed at 4 ms. For each spectrum 128 transients were acquired into 32 000 data points, with a spectral width of 10 kHz. Conventional 1 H NMR spectroscopy was performed on aqueous animal brain tissue extracts. Samples were loaded onto a Bruker AV600 spectrometer (Bruker Avance) with an ambient probe temperature of 25 1C. Standard 1D 1 H NMR spectra were acquired at 600 MHz using the noesypr1d pulse sequence described above. The resulting free induction decays were multiplied by an exponential weight function corresponding to a line broadening of 0.3 Hz, prior to Fourier transformation.
Multivariate data analysis
Spectral data were reduced into 0.04 p.p.m. spectral buckets using the software program AMIX (Analysis of MIXtures version 2.5, Bruker) and exported into SIMCA P (version 11.0, Umetrics AB, Umeå, Sweden). Principal components analysis was applied to the data to discern the presence of inherent similarities of spectral profiles. Five spectra were found to have suboptimal suppression of the water signal, presenting as statistical outliers, and thus were omitted from further analysis. To identify metabolites-differentiating treatment/patient groups from control groups, projection to latent structure discriminant analysis (PLS-DA) was employed.
31,32 Spectra were further analyzed using PLS-DA on full-resolution spectral data, with an integrated orthogonal filter (O-PLS-DA) to remove confounding variation and focus solely on the effect of drug treatment. 33 
Confirmation of metabolite changes
Metabolites identified as contributing to differences between groups using multivariate analysis were manually quantitated by integrating the peaks specific for each metabolite in the original spectra using XWIN-NMR (version 3.5, Bruker). Peak heights were normalized to the integral of the entire aliphatic region between 0.5 and 4.5 p.p.m. for each spectrum. Analysis of variance (ANOVA) quantitation with Tukey's post hoc test was then performed on integrated values to identify metabolites differing between groups.
Results
Metabonomic analysis of human post-mortem brain tissue PLS-DA analysis of data obtained from human prefrontal cortex (a representative HRMAS 1 H NMR spectrum from the analysis is shown in Figure 1a ) yielded models illustrating clear differences between tissue from control subjects and bipolar patients in both gray and white matter (scores plots are provided in Supplementary Figure 1 available at Molecular Psychiatry's website). PLS-DA models for the 1.8-4.24 p.p.m. region were also constructed to avoid normalization artifacts caused by large lipid resonances. These models also showed clear separation between control and bipolar patients in both gray and white matter. Loadings for the PLS-DA analysis, as shown in Figure 1a , indicated the spectral regions that attributed to the separation between the control and bipolar groups. Bipolar patient tissue samples exhibited alterations in the levels of several metabolites including increases in myo-inositol, creatine and glutamate when compared with controls (see Table 2 for summary).
To assess the effects of patient mood stabilizer treatment on the analysis, PLS-DA models were also constructed to compare only unmedicated patient samples with controls. These models again showed a clear separation between control and bipolar patients in both gray and white matter. Samples with a medication history of mood stabilizer treatment were predicted into each model to identify medication effects. The samples from patients with a medication history showed a metabolic signature that was distinct from controls, but not from unmedicated patient samples (Figures 1b and c) .
Metabolite changes were further examined by manually integrating spectral regions and comparing the mean resonance intensities for tissue from bipolar patients and control subjects. This univariate analysis helped both to verify metabolite changes detected using multivariate analysis and to determine the level of metabolite changes associated with bipolar disorder. The fold changes were calculated and are shown in Table 2 . Statistical differences were determined using ANOVA with Tukey's post hoc test between groups. All of the metabolites identified with multivariate analysis were also found to be altered using univariate statistical analysis (P < 0.05).
Metabonomic analysis of animal model brain tissue PLS-DA analysis identified differences in the metabolic profiles of mood stabilizer-treated rat brain tissue as compared to control brain tissue in striatum and hippocampus samples (Figures 2a and b) . No statistically robust model could be established to differentiate between either of the mood stabilizer treatments and controls in the cortex samples. Further analysis using O-PLS-DA resulted in the identification of several metabolites responsible for separation of treatment groups in both the hippocampus ( Figure  2c ) and the striatum. Although many of the metabolite changes were consistent between drugs and tissues, each therapy generated its own unique metabolite profile. For example, in both the hippocampus and the striatum, decreased myo-inositol and creatine levels were detected following both lithium and valproate treatment, whereas increased GABA levels were only observed following lithium treatment, and increased glutamine levels were only observed following valproate treatment (results are summarized in Table 2) .
Integral values for metabolites identified using O-PLS-DA were then measured manually from the original 1 H NMR spectra. Fold changes and biologically significant ratios of metabolites were calculated from this analysis and are presented in (Y)cum = 92%; Q 2 = 73%) show clear separation between control and bipolar patient samples. These models were initially produced with data from untreated bipolar patients and controls. Data from drug-treated bipolar patients were subsequently predicted into the models. Treated samples do not cluster away from untreated, and do not cluster closer to controls. Table 2 . The metabolic changes identified as altered with multivariate analysis following drug treatment were all verified with univariate analysis (P < 0.05 one-way ANOVA with Tukey's post hoc test) with the exceptions of lactate (P = 0.15) and GABA (P = 0.09) in the hippocampus (following lithium treatment) which showed a trend in the same direction. No changes were seen in the levels of a number of biologically relevant metabolites including NAA, glutamate, choline, taurine, succinate and alanine when manually integrated.
Discussion

Post-mortem brain tissue analysis
To the best of our knowledge, this is the first study to report a 1 H NMR spectroscopy-based analysis of postmortem brain tissue from patients with bipolar disorder. This approach has advantages over in vivo MRS in that a higher level of spectral resolution is achieved.
Brain tissue samples from patients who died with a diagnosis of bipolar disorder were well matched, with no significant differences from controls for key demographic variables, including age, gender, postmortem interval and pH of tissue (Table 1) . Medication treatment history of the patients could not be controlled for with the available samples, however, and samples from patients both with and without a medication history were used. The mood state at the time of death was unknown. These factors remain limitations of the study. Although previous data suggest that there may be mood state-specific metabolic differences in bipolar disorder, no clear statespecific pattern has yet emerged. 34 The samples used here were prepared and analyzed along with brain samples of patients who died with a diagnosis of schizophrenia. Data from the schizophrenia analysis have been previously published, and none of the findings in bipolar disorder described here were found in the schizophrenia samples. 16 Both gray and white matter bipolar tissue were separated well from the corresponding control tissue based on PLS-DA models (Figures 1b and c) . A number of metabolites were found to contribute to this separation including myo-inositol, glutamate, lactate, phosphocholine and creatine ( Figure 1a ; Table 2 ). This is in accordance with previous in vivo [37] [38] [39] Glutamate and phosphocholine are unresolvable in in vivo spectra, however, and many studies normalize 1 H MRS spectra to the creatine peak precluding it from being quantified. Myo-inositol and creatine changes seen in the bipolar patient samples were mirrored by opposing changes seen in rat brain tissue after chronic treatment with either valproate or lithium. An increase in glutamate levels was further mirrored by changes in GABA levels and glutamate metabolism in the animal models suggesting complementary effects of mood stabilizer treatment. All observations were found to be statistically robust. The majority of fold changes were between 4 and 8%, although some were as high as 20%. As brain tissue and extracellular fluids are normally held under tight homeostatic control, it is likely that all of these consistent changes are of physiological importance. The significance of these findings is discussed further below.
To determine the effect of mood-stabilizing medication, the human post-mortem data were analyzed to identify differences between medicated and unmedicated patient samples. The medicated samples did not show a metabolic signature distinct from the unmedicated patient samples, nor did they more closely resemble controls (Figures 1b and c) . Data on the medication history of the patients had been obtained from clinical records, however, and serum levels of the medications were not obtained at the time of death. Thus, there is no proof that the patients had been taking their prescribed medication prior to Figure 2 Multivariate analysis of conventional high-resolution 1 H NMR spectra generated from rat brain extracts. Crossvalidated projection to latent structure discriminant analysis (PLS-DA) score plots showing movement in metabolic space caused by mood stabilizer treatment in (a) the hippocampus (R 2 (X)cum = 35%; R 2 (Y)cum = 74%; Q 2 = 55%) and (b) the striatum (R 2 (X)cum = 51%; R 2 (Y)cum = 58%; Q 2 = 41%). In both tissue regions, score plots showed separation between control and mood stabilizer-treated rats primarily in the first principal component t [1] , whereas the second principal component t [2] showed differences between the two mood stabilizer treatments. (c) O-PLS-DA loading coefficient plots generated from analysis of spectra from the hippocampus for both lithium and valproate paradigms. The plots show spectral descriptors presenting differences between treatment groups, whereby the direction of change is indicated by signal orientation (positive coefficient values correspond to spectral regions positively covarying with drug treatment while negative coefficient values correspond to spectral regions positively covarying with controls). The color of the signal is proportional to the strength of the correlation with treatment (red indicates highest correlation and blue indicates no correlation) based on r 2 values. In the valproate vs control plot, for example, the most significant difference between the two treatments is in the concentration of myo-inositol.
death. In fact, four of the six patients medicated with either lithium or valproate committed suicide, an indication that the medications had either not been effective or more likely had been discontinued by the patients prior to committing suicide. The effect of the medications on the disease profile, therefore, cannot be ascertained conclusively from this post-mortem analysis.
Mood stabilizer-treated animal brain tissue analysis Animal models of chronic mood stabilizer treatment were investigated and drug-specific changes in metabolites were identified and compared with changes observed in post-mortem human brain samples. The present study is the first to investigate the effects of chronic oral mood stabilizer treatment on specific brain regions using high-resolution 1 H NMR spectroscopy.
The effect of the medication was determined on baseline animal brain tissue with the assumption that any observed molecular changes would have biochemical relevance to human brain tissue in the pathological state. This method has been used extensively to study the pharmacology of psychiatric medications. 7, 40 The human prefrontal cortex, the post-mortem brain area under investigation here, has no known anatomical correlate in the rat brain. The approach here, therefore, was to examine the medication's effect in several different rat brain regions with the assumption that the changes that were found consistently in those regions would likely occur in the rat equivalent to the prefrontal cortex. Most metabolic changes were found both in the hippocampus and striatum; furthermore, the alterations found in both brain areas showed the same directional change (results are reported in Table 2 ). No significant metabolic changes could be identified, however, in rat cortex samples. This could imply that some brain regions are preferentially targeted by mood-stabilizing drugs.
Changes common to both mood stabilizers Myo-inositol. Chronic treatment with both lithium and valproate resulted in a significant reduction of myo-inositol in both the rat hippocampus and striatum. Interestingly, this decrease countered the elevated levels observed in post-mortem tissue of bipolar patients (Table 2) .
Myo-inositol depletion is a well-characterized effect of lithium treatment and has also been found to occur after valproate treatment. 41, 42 The confirmation of this result adds confidence to the validity of our technical approach and analysis.
Both the cause and the consequences of myoinositol depletion with mood stabilizer treatment remain unknown. Myo-inositol is a significant intracellular osmolyte, and the changes may indicate alterations in tissue osmolarity. 21, 43 Additionally, the metabolite is known to be more abundant in glia than in neurons, 44 and the change may thus suggest neuronal atrophy in the disorder and a shift in the neuronal/glial balance toward neuronal cells with mood stabilizer treatment.
Both valproate and lithium have been shown to interact with the intracellular transport and biosynthesis of myo-inositol in the cell, [45] [46] [47] possibly explaining the observed decrease. Both also downregulate the inositol triphosphate second messenger system. 41 A depletion in myo-inositol could, potentially, exacerbate this downregulation. The decrease in myoinositol levels after lithium treatment has been shown to occur prior to its therapeutic effect, 48 thus, the depletion may represent an upstream event in the therapeutic mechanism of this medication.
Creatine. Chronic lithium and valproate treatment also reduced creatine levels in the rat brain, opposing an increase in the metabolite found in the patient post-mortem brain tissue. Creatine stores energy for the cell by means of a phosphate covalent bond in a similar manner to ATP/ADP. A decrease in creatine levels may, therefore, implicate an energetic shift in the brain with mood stabilizer treatment, causing a depletion of its energy storage capacity. This could possibly oppose a metabolic abnormality reflected in an increase of the metabolite with the disorder. In vivo brain imaging studies using 31 P MRS have indicated altered phosphorylation of either creatine or ATP in the brain tissue of patients (for review, see Kato 49 ). Molecular studies on the post-mortem tissue of patients have also indicated mitochondrial abnormalities. 50, 51 These findings, therefore, suggest a change in energy metabolism in the bipolar brain, consistent with our creatine result. Decreased creatine kinase mRNA levels 52 have also been reported in the post-mortem brain tissue of patients. This change may be compensation for an increase in creatine levels, although further work is needed to determine the metabolic equilibrium of creatine and phosphocreatine in the disorder.
Creatine is also a primary intracellular osmolyte, and the alteration in creatine may therefore indicate osmoregulatory changes in the disorder that are reversed by mood stabilizer treatment. In addition, both phosphocreatine and creatine levels can also mediate glutamate signaling, consistent with an alteration in neurotransmission. 53, 54 Decreased creatine levels have previously been observed in rat brain after a short treatment course of mood stabilizers. 42 However, a second study with a short treatment course found creatine to be unchanged, but also failed to identify myo-inositol depletion after lithium treatment. 55 This is the first report to show creatine decreasing after long-term treatment with mood-stabilizing medications.
A change in creatine with medication treatment and in the native disease pathophysiology would certainly render this metabolite to be a poor 'internal standard' to normalize in vivo 1 H MRS data in studies of bipolar disorder as has been noted previously. 42 Changes specific to valproate Glutamine and glutamate/glutamine ratio. Chronic valproate treatment increased glutamine levels in animal brain tissue and, to a greater extent, decreased the glutamate/glutamine ratio. Glutamate levels alone were not significantly altered. A change in glutamate/glutamine cycling may indicate a change in glutamate signaling, without a change in overall glutamate levels in the brain. Glutamate is the most common excitatory neurotransmitter in the brain. After its release, it is taken up by glial cells and converted into glutamine before being shuttled back into neurons where it is reconverted into glutamate. This glutamate-glutamine cycle between cell types is central to normal brain function and the rate of this cycle is indicative of glutamatergic activity. 56 Thus, a decrease in the glutamate/glutamine ratio may indicate that valproate elicits a general change in glutamatergic activity in the brain. This potential change in glutamate/glutamine cycling would counter the result in the post-mortem brain analysis that found increased levels of glutamate in bipolar samples.
A number of studies have shown altered neuronal activity in the bipolar prefrontal cortex with the disorder, including functional magnetic resonance imaging [57] [58] [59] and positron emission tomography studies. 60, 61 As glutamate is the predominant excitatory neurotransmitter in the brain, these studies support the interpretation that changes in glutamate signaling may be a feature of the disorder. To study the effect of valproate on glutamate signaling further, 13 C studies of metabolism in the animal brain allowing quantitative analysis of glucose or glutamate metabolism 62 could be undertaken after chronic valproate treatment.
Changes specific to lithium GABA. GABA is the primary inhibitory neurotransmitter in the brain. The observed increase in GABA after chronic lithium treatment could thus indicate a general increase of inhibitory neurotransmission. This result is consistent with several studies showing lithium to induce an acute and subacute increase of GABA in the rat brain. [63] [64] [65] GABA receptor binding has also previously been found to be decreased in rat brain after chronic lithium treatment, indicating a downregulation of GABA receptors, potentially through overactivation of the system. 66 This is the first report of an increase in GABA levels after chronic lithium treatment. The resulting increase in inhibitory neurotransmission could counteract increased excitatory neurotransmission resulting from elevated levels of glutamate such as those observed in our bipolar post-mortem analysis.
Scyllo-inositol. Scyllo-inositol was found to be increased in the animal brain after chronic lithium treatment. As scyllo-inositol can be readily converted into and from myo-inositol, 67 this increase provides further evidence for a disruption of the inositol signaling pathway associated with lithium treatment. Because the metabolite change appears following lithium, but not following valproate treatment, the increase may be useful for distinguishing between the effects of each drug on the inositol system.
Lactate. An increase of lactate was found following lithium treatment. Lactate levels increase with anaerobic metabolism, further indicating a metabolic shift in the brain with lithium treatment. Lactate has also been shown to increase as a consequence of ischemic neuronal damage in the brain. Although somewhat controversial, it has also been suggested that lactate may provide an alternate energy source for the brain, 68, 69 or may be involved in protective preconditioning. 69, 70 Further work is thus required to clarify the role of lactate in the mood-stabilizing mechanism of lithium. Levels of lactate were also found to be increased in the post-mortem brain tissue of patients with bipolar disorder, consistent with the observed creatine changes discussed above suggesting an alteration in energy metabolism. Lactate increases have previously been noted using in vivo MRS. 37, 39 Phosphoethanolamine and phosphocholine. Phosphoethanolamine and phosphocholine are precursors to membrane phospholipids in the cell. An increase in these two metabolites and a decrease in ethanolamine after lithium treatment may implicate altered lipid turnover in the striatum. Lithium has been shown to decrease arachidonic acid turnover profoundly in the brain (for review, see Rapoport and Bosetti 71 ) and affects the levels of COX-2 and PGE2 enzymes that metabolize the molecule. 72 As arachidonic acid is readily stored in the cell membrane of the brain, its downregulation may correlate with a change in phospholipid turnover with lithium treatment. It is important to note that this change in membrane precursors was only found in the striatum, indicating a region-specific change. Valproate has also been shown to affect arachidonic acid turnover, 73 but neither phosphocholine nor phosphoethanolamine levels were affected in this study. However, phosphocholine was found to be increased in the post-mortem brain of our bipolar patients, suggesting that it may play a role in the pathophysiology and treatment of the disorder.
Mood-stabilizing medication did not alter N-acetyl aspartate levels in rat brain N-acetyl aspartate is a metabolite synthesized in mitochondria which is commonly used as a marker of neuronal viability: NAA increases during neurogenesis 74 and decreases as a result of diverse neural pathologies. 75, 76 NAA has recently been found to be increased in brain tissue using 1 H MRS in a group of bipolar patients and control subjects following chronic treatment with lithium, 11 and has also been reported to be increased in lithium-treated patients when compared to control subjects and untreated bipolar patients. 10 However, a recent clinical study on control subjects taking chronic lithium showed no changes in NAA. 77 It remains unclear whether the NAA increase after lithium treatment is a diseasespecific effect, or an effect on baseline brain chemistry. In our study, neither chronic lithium nor chronic valproate treatment increased NAA levels in the rat brain. This observation would be consistent with a disease-specific effect of lithium on NAA that may not occur in the non-disease brain. No effect on NAA was seen after short-term treatment (2 weeks) with lithium in another study using animal brain tissue. 78 Future studies are warranted to test whether an increase in NAA after lithium treatment in bipolar patients constitutes a biomarker for a pathologydependent medication effect and whether this effect is associated with symptom improvement.
Conclusions
In this study, a pattern of metabolic perturbations was identified in the post-mortem tissue of patients who died with a diagnosis of bipolar affective disorder, and elements of this signature were found to be inversely altered in rats treated with mood-stabilizing drugs. Glutamate was found to be increased in patient brain tissue, while the glutamate/glutamine ratio was decreased in valproate-treated rat brain and GABA levels were increased following lithium treatment. These findings imply that the balance between excitatory and inhibitory neurotransmission may be changed in both the pathogenesis and treatment of bipolar disorder. Creatine and myo-inositol levels were also found to be altered in patients and mood stabilizer-treated rats (in opposing directions). At this point, it is not clear how exactly these opposing metabolic changes relate to the pathophysiology and alleviation of symptoms in bipolar disorder. However, our findings suggest that a reversal of metabolic disturbances in the brain may be crucial to the mechanism of action of valproate and lithium. Further work is thus warranted to better understand these metabolic alterations, with the ultimate goal of designing better treatments for this devastating psychiatric condition.
